Nanoparticles (NPs)
concentration directly impacts the dose delivered
to target tissues by nanocarriers. The evaluation of this parameter
is required during NPs developmental and quality control stages, for
setting dose–response correlations and for evaluating the reproducibility
of the manufacturing process. Still, faster and simpler procedures,
dismissing skilled operators and post-analysis conversions are needed
to quantify NPs for research and quality control operations, and to
support result validation. Herein, a miniaturized automated ensemble
method to measure NPs concentration was established under the lab-on-valve
(LOV) mesofluidic platform. Automatic NPs sampling and delivery to
the LOV detection unit were set by flow programming. NPs concentration
measurements were based on the decrease in the light transmitted to
the detector due to the light scattered by NPs when passing through
the optical path. Each analysis was accomplished in 2 min, rendering
a determination throughput of 30 h–1 (6 samples
h–1 for n = 5) and only requiring
30 μL (≈0.03 g) of NPs suspension. Measurements were
performed on polymeric NPs, as these represent one of the major classes
of NPs under development for drug-delivery aims. Determinations for
polystyrene NPs (of 100, 200, and 500 nm) and for NPs made of PEGylated
poly-d,l-lactide-co-glycolide (PEG–PLGA,
a biocompatible FDA-approved polymer) were accomplished within 108–1012 particles mL–1 range,
depending on the NPs size and composition. NPs size and concentration
were maintained during analysis, as verified for NPs eluted from the
LOV by particle tracking analysis (PTA). Moreover, concentration measurements
for PEG–PLGA NPs loaded with an anti-inflammatory drug, methotrexate
(MTX), after their incubation in simulated gastric and intestinal
fluids were successfully achieved (recovery values of 102–115%,
as confirmed by PTA), showing the suitability of the proposed method
to support the development of polymeric NPs targeting intestinal delivery.